Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.
AllAAOIABUSABVXACADACRVADMAAGIOALMSALMUALTSAPGEARTVASXAUPHAVAVAVPTAXTIBCRXCAICAKECEGCELCCEPCGONCIENCNCCOGTCRCLCTMXCTRIDKNGDUOLFLUTGCTGLWGOOGGPCRHALOHCAHIMSHOODHWMIDYAIRENIVVDKALAKALVKRYSLENZLEVILITELQDALRMRLULULUNRMDGLMESOMIRMMOHMPWRMTCHMUMVSTNBISNKENRIXNUENVAXNXPIOKUROLMAONCONTOORKAOSCRPDFSPHATPOETPRLDPYGRBLXRDDTRIGLRKLBSGHCSPRYSRPTTARSTBPHTHTRVITSHATTMIUNHVEONVORWVEXFORZBIOZLABZYME
The Biotech Anomaly: Why the Street is Dead Wrong on ACADIA Pharmaceuticals
2026-04-18BullishStrongChange from report: -11.4%1M: -6.3%3M: +13.6%
ACADIA's stock fell despite strong 2025 earnings, $391M net income, and a $1.28B 2026 outlook. Major funds are accumulating shares, and recent trading data signals a powerful reversal is underway.
The Asymmetric Disconnect: Why Wall Street is Mispricing ACADIA's $1 Billion Transformation
2026-03-27BullishStrongChange from report: -5.6%1M: +7.5%3M: +21.4%
ACADIA's stock is mispriced. It's a profitable $1B+ revenue company with $820M cash, yet trades low due to misunderstood tax-related insider sales and temporary IRA charges. The market ignores its strong financials and pipeline.